Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
François Raffi,Anita Rachlis,Hans‐Jürgen Stellbrink,W. D. Hardy,Carlo Torti,Chloe Orkin,Mark Bloch,Daniel Podzamczer,Vadim Pokrovsky,Federico Pulido,Steve Almond,David M. Margolis,Clare Brennan,Sherene Min